CMC Icos Biologics said today that it has put a major expansion of its Bothell facility on hold in a bid to save cash amid the economic downturn.

Share story

CMC Icos Biologics said today that it has put a major expansion of its Bothell facility on hold in a bid to save cash amid the economic downturn.

“With the current challenges of the global economy, we must carefully manage our resources,” President Gustavo Mahler said in a statement.

The expansion, announced in September and scheduled for completion in 2010, would have nearly doubled the company’s 141-strong workforce and quintupled its capacity to churn out biotechnology compounds on contract. The project was estimated to cost $35 million.

CMC Icos Biologics said it hasn’t set a new completion date yet, and wouldn’t do so in the near term.

CMC Icos Biologics was formed when Danish company CMC acquired the contract manufacturing unit of Icos a few months after the local biotech success was acquired — and essentially dissolved — by pharmaceutical giant Lilly.

Ángel González: 206-515-5644 or agonzalez@seattletimes.com